Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response

doi:10.1084/jem.170.4.1091

This Article

	Full Text (PDF, 699K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Irwin, M. J.
	Articles by Sherman, L. A.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Irwin, M. J.
	Articles by Sherman, L. A.


Social Bookmarking

	What's this?

ARTICLES

Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response

MJ Irwin, WR Heath and LA Sherman
Department of Immunology, Scripps Clinic and Research Foundation, La Jolla, California 92037.

As compared with the vigorous T cell response normally observed against allogeneic MHC molecules, T cells recognize xenogeneic MHC molecules poorly. To define structural features of the MHC molecule important for such species-specific recognition, HLA-A2(A2)-specific murine CTL were examined for their recognition of transfected cell lines expressing the class I molecules A2 or A2/H-2Kb(A2/Kb). A2/Kb is a chimeric molecule consisting of the alpha 1 and alpha 2 domains of A2 and the alpha 3, transmembrane, and cytoplasmic regions of Kb. The majority of CTL clones showed enhanced recognition of transfected cell lines expressing this chimeric molecule. Enhanced recognition was shown to correlate with sensitivity of the CTL clones to inhibition by anti-CD8 antibody. These results suggested that CD8 may interact with class I in a species- specific manner, and that suboptimal CD8 interaction with the alpha 3 domain of xenogeneic molecules may be an important contribution to poor xenoreactivity. This conclusion was supported by the capacity of A2/Kb, but not A2 human cell transfectants, to induce a primary in vitro CTL xenoresponse specific for A2.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Assarsson, E., Sidney, J., Oseroff, C., Pasquetto, V., Bui, H.-H., Frahm, N., Brander, C., Peters, B., Grey, H., Sette, A. (2007). A Quantitative Analysis of the Variables Affecting the Repertoire of T Cell Specificities Recognized after Vaccinia Virus Infection. J. Immunol. 178: 7890-7901 [Abstract] [Full Text]
Rice, J., Dunn, S., Piper, K., Buchan, S. L., Moss, P. A., Stevenson, F. K. (2006). DNA Fusion Vaccines Induce Epitope-Specific Cytotoxic CD8+ T Cells against Human Leukemia-Associated Minor Histocompatibility Antigens.. Cancer Res. 66: 5436-5442 [Abstract] [Full Text]
Takaki, T., Marron, M. P., Mathews, C. E., Guttmann, S. T., Bottino, R., Trucco, M., DiLorenzo, T. P., Serreze, D. V. (2006). HLA-A*0201-Restricted T Cells from Humanized NOD Mice Recognize Autoantigens of Potential Clinical Relevance to Type 1 Diabetes.. J. Immunol. 176: 3257-3265 [Abstract] [Full Text]
Narayanan, K., Jaramillo, A., Benshoff, N. D., Campbell, L. G., Fleming, T. P., Dietz, J. R., Mohanakumar, T. (2004). Response of Established Human Breast Tumors to Vaccination with Mammaglobin-A cDNA. JNCI J Natl Cancer Inst 96: 1388-1396 [Abstract] [Full Text]
Liao, Y.-P., Wang, C.-C., Butterfield, L. H., Economou, J. S., Ribas, A., Meng, W. S., Iwamoto, K. S., McBride, W. H. (2004). Ionizing Radiation Affects Human MART-1 Melanoma Antigen Processing and Presentation by Dendritic Cells. J. Immunol. 173: 2462-2469 [Abstract] [Full Text]
McKinney, D. M., Skvoretz, R., Livingston, B. D., Wilson, C. C., Anders, M., Chesnut, R. W., Sette, A., Essex, M., Novitsky, V., Newman, M. J. (2004). Recognition of Variant HIV-1 Epitopes from Diverse Viral Subtypes by Vaccine-Induced CTL. J. Immunol. 173: 1941-1950 [Abstract] [Full Text]
Tsujimura, K., Obata, Y., Kondo, E., Nishida, K., Matsudaira, Y., Akatsuka, Y., Kuzushima, K., Takahashi, T. (2003). Thymus leukemia antigen (TL)-specific cytotoxic T lymphocytes recognize the {alpha}1/{alpha}2 domain of TL free from antigenic peptides. Int Immunol 15: 1319-1326 [Abstract] [Full Text]
Buslepp, J., Kerry, S. E., Loftus, D., Frelinger, J. A., Appella, E., Collins, E. J. (2003). High Affinity Xenoreactive TCR:MHC Interaction Recruits CD8 in Absence of Binding to MHC. J. Immunol. 170: 373-383 [Abstract] [Full Text]
Pancholi, P., Perkus, M., Tricoche, N., Liu, Q., Prince, A. M. (2002). DNA Immunization with Hepatitis C Virus (HCV) Polycistronic Genes or Immunization by HCV DNA Priming-Recombinant Canarypox Virus Boosting Induces Immune Responses and Protection from Recombinant HCV-Vaccinia Virus Infection in HLA-A2.1-Transgenic Mice. J. Virol. 77: 382-390 [Abstract] [Full Text]
Eiben, G. L., Velders, M. P., Schreiber, H., Cassetti, M. C., Pullen, J. K., Smith, L. R., Kast, W. M. (2002). Establishment of an HLA-A*0201 Human Papillomavirus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A*0201 Transgenic Mice. Cancer Res. 62: 5792-5799 [Abstract] [Full Text]
Firat, H., Cochet, M., Rohrlich, P.-S., Garcia-Pons, F., Darche, S., Danos, O., Lemonnier, F. A., Langlade-Demoyen, P. (2002). Comparative analysis of the CD8+ T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int Immunol 14: 925-934 [Abstract] [Full Text]
Peter, K., Brunda, M. J., Corradin, G. (2002). IL-12 Administration Leads to a Transient Depletion of T Cells, B Cells, and APCs and Concomitant Abrogation of the HLA-A2.1-Restricted CTL Response in Transgenic Mice. J. Immunol. 169: 63-67 [Abstract] [Full Text]
Palmowski, M. J., Choi, E. M.-L., Hermans, I. F., Gilbert, S. C., Chen, J.-L., Gileadi, U., Salio, M., Van Pel, A., Man, S., Bonin, E., Liljestrom, P., Dunbar, P. R., Cerundolo, V. (2002). Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols. J. Immunol. 168: 4391-4398 [Abstract] [Full Text]
Sharland, A., Patel, A., Lee, J. H., Cestra, A. E., Saidman, S., Waneck, G. L. (2002). Genetically Modified HLA Class I Molecules Able to Inhibit Human NK Cells Without Provoking Alloreactive CD8+ CTLs. J. Immunol. 168: 3266-3274 [Abstract] [Full Text]
Miconnet, I., Koenig, S., Speiser, D., Krieg, A., Guillaume, P., Cerottini, J.-C., Romero, P. (2002). CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide. J. Immunol. 168: 1212-1218 [Abstract] [Full Text]
Pierce, R. A., Field, E. D., Mutis, T., Golovina, T. N., Kap-Herr, C. V., Wilke., M., Pool, J., Shabanowitz, J., Pettenati, M. J., Eisenlohr, L. C., Hunt, D. F., Goulmy, E., Engelhard, V. H. (2001). The HA-2 Minor Histocompatibility Antigen Is Derived from a Diallelic Gene Encoding a Novel Human Class I Myosin Protein. J. Immunol. 167: 3223-3230 [Abstract] [Full Text]
Miconnet, I., Coste, I., Beermann, F., Haeuw, J.-F., Cerottini, J.-C., Bonnefoy, J.-Y., Romero, P., Renno, T. (2001). Cancer Vaccine Design: A Novel Bacterial Adjuvant for Peptide-Specific CTL Induction. J. Immunol. 166: 4612-4619 [Abstract] [Full Text]
Men, Y., Miconnet, I., Valmori, D., Rimoldi, D., Cerottini, J.-C., Romero, P. (1999). Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/Kb Transgenic Mice. J. Immunol. 162: 3566-3573 [Abstract] [Full Text]
Theobald, M., Biggs, J., Hernandez, J., Lustgarten, J., Labadie, C., Sherman, L. A. (1997). Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes. JEM 185: 833-842 [Abstract] [Full Text]
Sherman, L., Hesse, S., Irwin, M., La Face, D, Peterson, P (1992). Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258: 815-818 [Abstract]
Miconnet, I., Servis, C., Cerottini, J.-C., Romero, P., Levy, F. (2000). Amino Acid Identity and/or Position Determines the Proteasomal Cleavage of the HLA-A*0201-restricted Peptide Tumor Antigen MAGE-3271-279. J. Biol. Chem. 275: 26892-26897 [Abstract] [Full Text]